<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005038</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067627</org_study_id>
    <secondary_id>CHNT-IL2-MAXAMINE</secondary_id>
    <secondary_id>EU-99048</secondary_id>
    <secondary_id>MAXIM-MP-502</secondary_id>
    <nct_id>NCT00005038</nct_id>
  </id_info>
  <brief_title>Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Randomized Phase II Study to Evaluate the Efficacy of Combined Immunotherapy With Subcutaneous Interleukin-2 and Maxamine in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer&#xD;
      cells. Histamine dihydrochloride may prolong survival and improve quality of life in patients&#xD;
      with metastatic kidney cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-2 with or&#xD;
      without histamine dihydrochloride in treating patients who have metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical efficacy and safety of subcutaneous (SC) histamine&#xD;
           dihydrochloride given in conjunction with SC recombinant human interleukin-2 in patients&#xD;
           with stage IV renal cell carcinoma in terms of survival at 1 year, objective tumor&#xD;
           response rate, duration of response, and median survival.&#xD;
&#xD;
      OUTLINE: This is a randomized, open label study. Patients are randomized to receive&#xD;
      interleukin-2 (IL-2) with or without histamine dihydrochloride.&#xD;
&#xD;
        -  Arm I: Patients receive IL-2 subcutaneously (SC) once daily and histamine&#xD;
           dihydrochloride SC twice daily on days 1-5 of weeks 1-3 followed by 2 weeks of rest.&#xD;
&#xD;
        -  Arm II: Patients receive IL-2 as in arm I. Treatment continues for a minimum of 2&#xD;
           courses in both arms in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>histamine dihydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell carcinoma&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  No clinical evidence of CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin greater than 10.0 g/dL&#xD;
&#xD;
          -  WBC greater than 3,000/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  Bilirubin less than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No abnormal cardiac function by resting ECG&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV and FVC at least 70% predicted&#xD;
&#xD;
          -  SaO2 at least 90% by pulse oximetry&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No clinically significant acute viral, bacterial, or fungal infection requiring&#xD;
             specific therapy&#xD;
&#xD;
          -  No pheochromocytoma&#xD;
&#xD;
          -  No glaucoma&#xD;
&#xD;
          -  No other concurrent ongoing active malignancy except carcinoma in situ of the cervix&#xD;
             or localized squamous or basal cell carcinoma of the skin&#xD;
&#xD;
          -  No serious recent nonmalignant medical complication that would preclude study therapy&#xD;
&#xD;
          -  No organ grafts except skin grafts, blood transfusions, or bone marrow or stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No prior documented asthma or systemic allergic reaction within past 5 years&#xD;
&#xD;
          -  No history of seizures, CNS disorders, or psychiatric disability that would preclude&#xD;
             study compliance&#xD;
&#xD;
          -  No medical, sociologic, or psychological impediment that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  No active peptic or esophageal ulcer disease&#xD;
&#xD;
          -  No prior peptic or esophageal ulcer disease with history of bleeding&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 24 hours since prior steroids&#xD;
&#xD;
          -  No concurrent steroids including steroid therapy for documented adrenal failure or&#xD;
             septic shock&#xD;
&#xD;
          -  Concurrent noncorticosteroid hormones for nonmalignancy conditions allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior extensive radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to measurable malignant masses&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 24 hours since prior beta blockers or clonidine&#xD;
&#xD;
          -  No other concurrent systemic antimalignancy therapy&#xD;
&#xD;
          -  No other concurrent antitumor agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent beta blockers or clonidine&#xD;
&#xD;
          -  No concurrent H2 receptor antagonists (e.g., Zantac, Tagamet) (arm I only)&#xD;
&#xD;
          -  No concurrent antihistamines except to treat acute colds or allergy symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Middleton, MD, PhD, MBChB, MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2001</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

